$6.61 Million is the total value of Biomark Capital Management Co. LLC's 2 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ADMA | ADMA BIOLOGICS, INC. | $6,593,000 | +43.3% | 1,433,304 | 0.0% | 99.80% | +1848.5% | |
| MBVXQ | New | MABVAX THERAPEUTICS HOLDINGS, INC. | $13,000 | – | 8,903 | +100.0% | 0.20% | – |
| MBVX | Exit | MABVAX THERAPEUTICS HOLDINGS, INC. | $0 | – | -26,708 | -100.0% | -0.02% | – |
| JUNO | Exit | JUNO THERAPEUTICS, INC. | $0 | – | -1,864,174 | -100.0% | -94.86% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Biomark Capital Fund IV GP LLC #1
- David S. Wetherell #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-04-20
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ADMA BIOLOGICS, INC. | 12 | Q3 2018 | 100.0% |
| JUNO THERAPEUTICS, INC. | 9 | Q4 2017 | 95.0% |
| MABVAX THERAPEUTICS HOLDINGS, INC. | 6 | Q4 2017 | 0.2% |
| MABVAX THERAPEUTICS HOLDINGS, INC. | 3 | Q2 2016 | 0.2% |
| MABVAX THERAPEUTICS HOLDINGS, INC. | 3 | Q3 2018 | 0.2% |
View Biomark Capital Management Co. LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-10-24 |
| 13F-HR | 2018-08-09 |
| 13F-HR | 2018-04-20 |
| 13F-HR | 2018-02-13 |
| 13F-HR | 2017-10-30 |
| 13F-HR | 2017-08-08 |
| 13F-HR | 2017-05-11 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-09 |
| 13F-HR | 2016-08-12 |
View Biomark Capital Management Co. LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.